Article Contents ::
- 1 The Brand Name BIOSIM Has Generic Salt :: Simvastatin
- 2 BIOSIM Is From Company Biochem Priced :: Rs. 54.00/99.00
- 3 BIOSIM have Simvastatin is comes under Sub class Anti Hyperlipidemics of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hyperlipidemics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BIOSIM Has Generic Salt :: Simvastatin
BIOSIM Is From Company Biochem Priced :: Rs. 54.00/99.00
BIOSIM have Simvastatin is comes under Sub class Anti Hyperlipidemics of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hyperlipidemics
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Simvastatin | TAB | Rs. 54.00/99.00 | 10-Oct |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10-Oct |
| BIOSIM | Biochem | 10/20;MG | 10-Oct | Rs. 54.00/99.00 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Biochem :: BIOSIM | Simvastatin | Cardiovascular System | Anti Hyperlipidemics |
Indications for Drugs ::
Hyperlipidaemias, stroke prevention
Drug Dose ::
Adult: PO Hyperlipidaemias Initial: 10-20 mg/day. May adjust dose at intervals of at least 4 wk. Max: 80 mg/day. CV risk reduction In high-risk patients: 20-40 mg once daily. Moderate-risk patients: 10 mg once daily.
Contraindication ::
Acute liver disease or unexplained persistent elevations of serum transaminases. Pregnancy, lactation. Porphyria. Patients of Chinese descent should not take 80 mg dose w/ lipid-modifying dose of niacin-containing products (?1 g/day).
Drug Precautions ::
History of liver disease. Increased risk of rhabdomyolysis in severe infection, hypotension, major surgical trauma, uncontrolled seizures or severe metabolic, endocrine and electrolyte disorder. Alcoholism; premenarcheal females; children <10 yr. Discontinue treatment if there is marked or persistent increase in serum-aminotransferase concentrations. Drug Side Effects ::
Headache, nausea, flatulence, heartburn, abdominal pain, diarrhoea/constipation, dysgeusia; dose-related myopathy (e.g. myalgia, muscle weakness and dark urine); serum transaminases and CPK elevations; hypersensitivity; lens opacities; blurring of vision; dizziness; sexual dysfunction; insomnia; depression and upper respiratory symptoms. Potentially Fatal: Severe rhabdomyolysis with acute renal failure.
Pregnancy category ::
5
Drug Mode of Action ::
Simvastatin, an antilipemic agent is a competitive inhibitor of HMG-CoA reductase, the enzyme that catalyses the early and rate-limiting step in cholesterol biosynthesis reduces total cholesterol, LDL-cholesterol and triglycerides and increases HDL-cholesterol levels.
Drug Interactions ::
May increase bleeding risk w/ anticoagulants. Reduced serum levels w/ bosentan, efavirenz and rifampicin. Increased risk of myopathy and rhabdomyolysis w/ colchicine, amiodarone, verapamil and diltiazem. Increased risk of myopathy w/ amlodipine, fusidic acid. Potential reduction of cytotoxic effect of rituximab. Increased hepatotoxicity w/ ezetimibe. Potentially Fatal: Concurrent use w/ itraconazole, ketoconazole, posaconazole, clarithromycin, erythromycin, telithromycin, nefazodone, niacin, HIV protease inhibitors (e.g. nelfinavir), boceprivir, telaprevir, gemfibrozil, ciclosporin and danazol may increase the risk of myopathy, rhabdomyolysis and acute renal failure.
